Improved pulmonary function following pirfenidone treatment in a patient with progressive interstitial lung disease associated with systemic sclerosis

被引：36
|
作者：
Udwadia, Zarir F. [1 ]
Mullerpattan, Jai B. [1 ]
Balakrishnan, Canchi [2 ]
Richeldi, Luca [3 ]
机构：
[1] PD Hinduja Natl Hosp & Med Res Ctr, Dept Resp Med, Veer Savarkar Marg, Bombay 400016, Maharashtra, India
[2] PD Hinduja Natl Hosp & Med Res Ctr, Dept Rheumatol, Bombay, Maharashtra, India
[3] Univ Modena & Reggio Emilia, Dept Resp Med, Ctr Rare Lung Dis, Chair Interstitial Lung Dis, Modena, Italy
来源：
LUNG INDIA | 2015年 / 32卷 / 01期
关键词：
Interstitial lung disease; pirfenidone; systemic sclerosis;
D O I：
10.4103/0970-2113.148451
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
Pirfenidone is an anti-fibrotic drug which has been approved for the management of patients with Idiopathic Pulmonary Fibrosis (IPF). However, its role in interstitial lung disease (ILD) due to other causes such as systemic sclerosis (SSc) is not clear. We present a case of a patient with SSc associated ILD who showed a subjective as well as objective improvement in lung function with pirfenidone.
引用
收藏
页码：50 / 52
页数：3
相关论文
共 50 条
  • [21] SLOW PROGRESSIVE INTERSTITIAL LUNG DISEASE ASSOCIATED WITH SYSTEMIC SCLEROSIS: DISTINCT DISEASE PHENOTYPE?
    Ananyeva, L.
    Ovsyannikova, O.
    Lesnyak, V.
    Koneva, O.
    Desinova, O.
    Starovoylova, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 1013 - 1013
  • [22] Lung Function and Survival In Systemic Sclerosis Associated Interstitial Lung Disease.
    Shadly, Samar M.
    Johnson, Sindhu R.
    Chau, Cathy
    Marras, Theodore K.
    ARTHRITIS AND RHEUMATISM, 2013, 65 : S291 - S292
  • [23] Interstitial Lung Disease Associated with Systemic Sclerosis
    Mismetti, Valentine
    Si-Mohamed, Salim
    Cottin, Vincent
    SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 45 (03) : 342 - 364
  • [24] Systemic Sclerosis Associated Interstitial Lung Disease
    Steen, Virginia
    Weir, Nargues
    CURRENT RESPIRATORY MEDICINE REVIEWS, 2015, 11 (02) : 110 - 118
  • [25] Systemic sclerosis associated interstitial lung disease
    Xanthouli, P.
    Hermann, W.
    Hunzelmann, N.
    Kreuter, M.
    PNEUMOLOGE, 2018, 15 (06): : 383 - 395
  • [26] Pirfenidone combined with corticosteroids in a patient with systemic lupus erythematosus-associated interstitial lung disease
    Yang, B. -B.
    Man, X. -Y.
    Zheng, M.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017, 31 (09) : E389 - E391
  • [27] SAFETY AND TOLERABILITY OF PIRFENIDONE IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE - THE LOTUSS STUDY
    Khanna, D.
    Albera, C.
    Fischer, A.
    Seibold, J. R.
    Raghu, G.
    Khalidi, N.
    Chung, L.
    Schiopu, E.
    Chen, D.
    Gorina, E.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 816 - 816
  • [28] Safety And Tolerability Of Pirfenidone In Patients With Systemic Sclerosis-Associated Interstitial Lung Disease - The Lotuss Study
    Khanna, D.
    Albera, C.
    Fischer, A.
    Khalidi, N.
    Raghu, G.
    Chung, L.
    Chen, D.
    Schiopu, E.
    Gorina, E.
    Tagliaferri, M.
    Seibold, J. R.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2015, 191
  • [29] Interstitial lung disease in systemic sclerosis - Treatment
    Hellmich, B
    Schnabel, A
    Bauer, T
    Schatz, H
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2002, 127 (10) : 520 - 522
  • [30] Current treatment of systemic sclerosis-associated interstitial lung disease
    Bes, Cemal
    Cetinkaya, Erdogan
    TUBERKULOZ VE TORAKS-TUBERCULOSIS AND THORAX, 2022, 70 (01): : 85 - 92
12345